ECO Animal Health Group plc (‘’ECO”)
ECO Animal Health Group plc (the “Group”) is pleased to announce the appointment of Christopher Wilks as Chief Financial Officer of ECO from 3 September 2019. Christopher Wilks has considerable experience in the fields of both finance and science. He is currently a non-executive director of Kromek Group plc, an AIM listed worldwide supplier of detection technology and was previously Chief Financial Officer of Signum Technology, a leading group of specialised engineering businesses operating in the safety and critical service flow control sector, which he co-founded in 2012. Prior to Signum Technology, Mr Wilks was Chief Financial Officer at Sondex plc, a specialist manufacturer of technical instruments for the oil and gas industry. Mr Wilks became the Chief Financial Officer of Sondex in 1997 and in June 2003 he successfully managed the listing of Sondex plc on the Main Market of the London Stock Exchange. Sondex was acquired by GE in 2007.
Mr Wilks began his successful career after graduating from the University of Durham with a BSc in Applied Physics and Electronics. Initially he joined Marconi Space Systems, applying his degree skills to the design of power systems for spacecraft. He then trained as a Chartered Accountant at Ernst & Young (now EY), and after qualifying as a Chartered Accountant in audit, he became a manager of its Corporate Finance team.
Kevin Stockdale, Financial Director, has resigned from the Board and shall remain with the Company.
Julia Trouse, Executive Director, has resigned from the Board and shall remain as Company Secretary in order to comply with QCA guidelines.
Brett Clemo, Executive Director, had informed the Board of his intention to retire in 2017 and will start his long planned for retirement on the 30th September 2019. He will not stand for re-election at the Company's Annual General Meeting scheduled to take place on 19 September 2019.
Following these board changes the board will comprise three independent non-executive directors being Richard Wood (Chairman), Andrew Jones and Tony Rawlinson and two executive directors being Marc Loomes (CEO) and Christopher Wilks (CFO), thereby fulfilling one of its Corporate Governance objectives stated in its 2019 Annual Report and Accounts Corporate Governance Statement of establishing an Independent Board with a majority of non-executive directors.
Marc Loomes, CEO of ECO, commented:
“I'm delighted to welcome Chris to our Board as CFO. He brings a wealth of experience, having successfully grown listed businesses, and is a great addition to our management team as we look to build on our momentum. I would like to take this opportunity to extend my sincere thanks to Kevin and Julia for the considerable contributions that they have made to the Board over many years. The Board would like to thank Brett for his invaluable contribution to the growth and development of ECO over the past 13 years and to wish him all the very best for his retirement.”
Christopher John Wilks is 55 years old and during the last five years immediately preceding the date of this announcement held the following directorships:
Kromek Group plc
Copper Bidco Ltd
Copper Midco 1 Ltd
Copper Midco 2 Ltd
Falcon Oilfield Services LLC
Filtration and Valves Ltd
Gall Thomson Environmental Ltd
Gall Thomson International Ltd
Klaw Products Ltd
Signum Technology Ltd
Vee Bee Filtration (UK) Ltd
Vee Bee Ltd
Mr Wilks was a director of Clearwater Industries between 1994 and 1996. In 1996, Clearwater Industries was put into liquidation and was sold two days later. The creditor shortfall was approximately £100,000.
There is no further information to be disclosed pursuant to Schedule Two Part (g) of the AIM Rules for Companies.
ECO Animal Health Group plc
Richard Wood, Chairman
Marc Loomes, CEO
020 8447 6906
020 3934 6637
N+1 Singer (Nominated Adviser & Joint Broker)
020 7496 3000
Peel Hunt LLP (Joint Broker)
Dr Christopher Golden
020 7418 8900
About ECO Animal Health Ltd
ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.
Copyright Business Wire 2019